Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542727 | 0.93 | AKT1 (0.36) | AKT1SIRT2SIRT1 | |
| SCHEMBL10026185 | 0.89 | AKT1 (0.39) | AKT1SIRT2SIRT1OPRM1OPRD1 | |
| SCHEMBL11964062 | 0.83 | AKT1 (0.42) | AKT1SIRT2SIRT1 | |
| SCHEMBL277489 | 0.83 | SIRT2 (0.41) | AKT1SIRT2SIRT1 | |
| SCHEMBL14755924 | 0.82 | AKT1 (0.41) | AKT1SIRT2SIRT1 | |
| SCHEMBL10066896 | 0.81 | CPB1 (0.32) | SIRT2SIRT1 | |
| SCHEMBL14016183 | 0.80 | AKT1 (0.40) | AKT1SIRT2SIRT1EPHX1 | |
| SCHEMBL12692606 | 0.80 | SIRT2 (0.36) | AKT1SIRT2SIRT1 | |
| SCHEMBL825245 | 0.78 | EPHX1 (0.39) | AKT1OPRM1OPRD1OPRK1PTGS1 | |
| SCHEMBL14753623 | 0.78 | SIRT2 (0.38) | AKT1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383380-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | NEKTAR THERAPEUTICS (US) | 2012-02-02 | — | — | US | disclosed |
| US-8084572-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2011-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | EPCAM, CD44, ECPAS | AKT1 3314/4885SIRT2 4437/4885SIRT1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.